Age-Related Effects of Exogenous Melatonin on Anxiety-like Behavior in C57/B6J Mice

Abstract

The synthesis of melatonin (MLT) physiologically decreases during aging. Treatment with MLT has shown anxiolytic, hypnotic, and analgesic effects, but little is known about possible age-dependent differences in its efficacy. Therefore, we studied the effects of MLT (20 mg/kg, intraperitoneal) on anxiety-like behavior (open field (OFT), elevated plus maze (EPMT), three-chamber sociability, and marble-burying (MBT) tests), and the medial prefrontal cortex (mPFC)-dorsal hippocampus (dHippo) circuit in adolescent (35–40 days old) and adult (three-five months old) C57BL/6 male mice. MLT did not show any effect in adolescents in the OFT and EPMT. In adults, compared to vehicles, it decreased locomotor activity and time spent in the center of the arena in the OFT and time spent in the open arms in the EPMT. In the MBT, no MLT effects were observed in both age groups. In the three-chamber sociability test, MLT decreased sociability and social novelty in adults, while it increased sociability in adolescents. Using local field potential recordings, we found higher mPFC-dHippo synchronization in the delta and low-theta frequency ranges in adults but not in adolescents after MLT treatment. Here, we show age-dependent differences in the effects of MLT in anxiety paradigms and in the modulation of the mPFC-dHippo circuit, indicating that when investigating the pharmacology of the MLT system, age can significantly impact the study outcomes.

Neural Correlates and Molecular Mechanisms of Memory and Learning

“…It also enables the investigation of structural changes in the brain and advances imaging techniques for clinical use [ 82 , 83 ]. Preclinical research and computational medicine are critical for unraveling the complexities of neurological and mental disorders, providing critical insights, facilitating treatment testing, and paving the way for novel therapeutics and personalized medicine [ 84 , 85 , 86 , 87 , 88 , 89 ].…”

Emerging Translational Research in Neurological and Psychiatric Diseases: From In Vitro to In Vivo Models

“…In summary, we aspire for this subject to act as a pivotal platform for the exploration of the neural foundations of neurological and psychiatric disorders. Researchers are attempting to open novel avenues for specialized treatment plans and preventive measures, with the ultimate aim of improving the quality of life of those suffering from these complex mental health conditions, by examining behavioral neuroscience from this perspective [82][83][84][85][86][87][88]. As our comprehension of the pathomechanisms underlying neuropsychiatry advances, we draw nearer to a future in which individuals can receive personalized care and support to conquer these challenging conditions.…”

From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment

“…Humans typically experience migraines, but preclinical research using animal models reveals the interaction of genetic and environmental factors contributing to neurological disorders like migraines [56][57][58][59][60][61][62][63][64][65][66][67]. These models simulate disease conditions, aiding in identifying pathogenic processes, evaluating symptoms and comorbidities, and discovering interventions [68][69][70][71][72][73][74]. The integration of preclinical and clinical research contributes to innovative therapeutics and personalized medicine [75][76][77][78].…”